JGC
ACH

J. Goldman & Co’s Accendra Health ACH Stock Holding History

J. Goldman & Co’s Portfolio ACH Stock Details ACH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-100
Closed -$910 – 567
2025
Q2 		$910 Buy
+100
New +$737 ﹤0.01% 436

Other funds holding ACH

CCM
Coliseum Capital Management Rowayton, Connecticut $1.22B AUM 18.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return
PCMI
Paradigm Capital Management Inc Albany, New York $2.61B AUM 78.58% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

J. Goldman & Co's ACH Position: Q3 2025 in Review

J. Goldman & Co sold out of Accendra Health (ACH) in Q3 2025, closing a stake of 734,797 shares — an estimated $6.69M sold.

J. Goldman & Co first reported a position in ACH in Q2 2025 and held it in 1 quarter. The position peaked at $6.69M in Q2 2025. 202 funds tracked by Wall St. Rank hold ACH as of Q3 2025.

  • J. Goldman & Co reported no remaining Accendra Health position as of Q3 2025 after selling out during the quarter.
  • J. Goldman & Co sold 734,797 Accendra Health shares in Q3 2025, an estimated $6.69M.
  • J. Goldman & Co first reported a position in Accendra Health in Q2 2025 and held it in 1 quarter.
  • J. Goldman & Co's Accendra Health position peaked at $6.69M in Q2 2025.
  • 202 funds tracked by Wall St. Rank held Accendra Health as of Q3 2025.

Based on J. Goldman & Co's 13F filing for Q3 2025, filed 14 Nov 2025.